Drug intelligence / Profile preview

ICP-923

Development stage: Preclinical
Lead developer: InnoCare Pharma
Modality: Small Molecules
Administration: Oral

Overview

ICP-923 is an oral small molecule drug developed by InnoCare Pharma. It acts as a potent IL-17A blocker, targeting the IL-17 receptor family. IL-17 is a pro-inflammatory cytokine that plays a key role in immune functional responses and the pathogenesis of various autoimmune diseases. Unlike monoclonal antibodies that target IL-17, ICP-923 offers the convenience of oral administration and can potently block both IL-17AA and IL-17AF binding to the IL-17 receptor[4][5]. As of June 2025, its highest development status is preclinical for autoimmune diseases[1][4].

Targets

IL-17A (Interleukin-17A)IL17RA (IL-17RA)

Beyond the preview

Go deeper on ICP-923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICP-923.

Explore the full profile